AMA Announces CPT Update for Pediatric COVID-19 Vaccine Candidate

The American Medical Association (AMA) announced that the Current procedural terminology (CPT) The code set has been updated by the CPT’s editorial board to include vaccine and administration codes for pediatric doses of the COVID-19 vaccine developed by Pfizer.

Provisional CPT codes may be used on condition that Pfizer’s two-dose regimen for the prevention of COVID-19 in children ages 5-11 is approved by the U.S. Food and Drug Administration (FDA) or get an emergency permit. The AMA is now releasing the CPT code update to ensure that electronic systems across the U.S. healthcare system are prepared in advance for possible FDA approval or approval.

“The AMA supports the goal of expanding COVID-19 vaccination protection to a wider age group of children,” said AMA President Gerald E. Harmon, MD. “A rigorous, transparent review process by the Federal Drug Administration and the Centers for Disease Control and Prevention will evaluate the safety and effectiveness of Pfizer’s COVID-19 vaccine for possible use in children ages 5-11. An open and comprehensive evaluation of the data from pediatric vaccine studies is crucial in order to instill the necessary public trust in COVID-19 vaccines for children under the age of 12. “

The development of vaccine-specific CPT codes has clinically distinguished each coronavirus vaccine and dosing schedule for better tracking, reporting, and analysis that supports data-driven planning and allocation. Unique CPT codes were previously issued for COVID-19 vaccines from AstraZeneca, Janssen (Johnson & Johnson), Moderna, Novavax and Pfizer.

To ensure accurate coding and reporting of COVID-19 vaccines and vaccination services, the AMA offers the following: Vaccine Code Finder Resource to identify the appropriate CPT code combination for the type and dose of COVID-19 vaccine that will be provided to each patient.

For quick reference, the new vaccine and administration codes assigned to Pfizer’s pediatric doses of COVID-19 vaccine are:

Vaccine product code

91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine, mRNA-LNP, spike protein, free of preservatives, dosage 10 µg / 0.2 ml, reconstituted diluent, tris-sucrose formulation, for intramuscular use

Vaccine Administration Codes

0071A Immunization Administration by Intramuscular Injection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus Disease) [COVID-19]) Vaccine, mRNA-LNP, spike protein, free of preservatives, 10 µg / 0.2 ml dosage, reconstituted diluent, tris-sucrose formulation; first dose

0072A Immunization Administration by Intramuscular Injection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus Disease) [COVID-19]) Vaccine, mRNA-LNP, spike protein, free of preservatives, 10 µg / 0.2 ml dosage, reconstituted diluent, tris-sucrose formulation; second dose

Short, medium and long descriptors for all new vaccination-specific CPT codes can be found on the page AMA website, along with other recent changes to the CPT code set that have helped streamline the public health response to SARS-CoV-2 virus and COVID-19 disease.

Changes to the CPT code set are accounted for through an open editorial process managed by the CPT editorial board that gathers broad input from the healthcare industry and beyond to ensure that CPT content meets the coding requirements of digital health, precision medicine, augmented Intelligence and others reflect aspects of a modern healthcare system. This rigorous editorial process keeps the CPT code set updated with contemporary medical science and technology so that it can fulfill its vital role as the trusted language of medicine today and as the code for its future.

Healthcare jobs